Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03999658
Recruitment Status : Not yet recruiting
First Posted : June 27, 2019
Last Update Posted : June 27, 2019
Sponsor:
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc.

Brief Summary:
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.

Condition or disease Intervention/treatment Phase
Peripheral T Cell Lymphoma Diffuse Large B Cell Lymphoma Biliary Tract Cancer Extranodal NK T Cell Lymphoma, Nasal Biological: STI-3031 Phase 2

Detailed Description:

This is an open-label, multicenter, global Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031 in patients with selected relapsed or refractory (R/R) malignancies. The study will be conducted as separate Phase 2, single arm substudies for each of the indications below:

  • Extranodal NK/T-cell lymphoma (ENKTL)
  • Peripheral T-cell lymphomas (PTCL)
  • Diffuse large B-cell lymphoma (DLBCL) with PD-L1 gene translocation, copy gain, amplification, polysomy detectable by a fluorescence in situ hybridization (FISH) assay or Epstein-Barr virus positivity (EBV+) as assessed by EBV-encoded small RNA (EBER) testing
  • Biliary tract cancers (BTC) (intrahepatic cholangiocarcinoma), extrahepatic cholangiocarcinoma or gallbladder cancer)

All participants will receive the study intervention, STI-3031.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Global Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Malignancies.
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : July 2024


Arm Intervention/treatment
Experimental: Extranodal NK/T-cell lymphoma (ENKTL)
Intravenous STI-3031 (anti-PD-L1 antibody)
Biological: STI-3031
anti-PD-L1 antibody
Other Name: IMC-001

Experimental: Peripheral T-cell lymphomas (PTCL)
Intravenous STI-3031 (anti-PD-L1 antibody)
Biological: STI-3031
anti-PD-L1 antibody
Other Name: IMC-001

Experimental: Diffuse large B-cell lymphoma (DLBCL)
Intravenous STI-3031 (anti-PD-L1 antibody)
Biological: STI-3031
anti-PD-L1 antibody
Other Name: IMC-001

Experimental: Biliary tract cancers (BTC)
Intravenous STI-3031 (anti-PD-L1 antibody)
Biological: STI-3031
anti-PD-L1 antibody
Other Name: IMC-001




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Approximately 24 months ]
    Percentage of participants achieving a Complete Response (CR) or Partial Response (PR) at any time during the study as assessed by an Independent Response Committee (IRC) per the Lugano criteria with LYRIC modification or RECIST 1.1


Secondary Outcome Measures :
  1. Objective Response Rate by treating physician [ Time Frame: Approximately 24 months ]
    Percentage of participants achieving a CR or PR at any time during the study as assessed by the Investigator per the Lugano criteria with LYRIC modification or RECIST 1.1

  2. Duration of Response [ Time Frame: Approximately 24 months ]
    Time from the first documentation of response (CR or PR) to the first documentation of progressive disease (PD) as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  3. Complete Response Rate [ Time Frame: Approximately 24 months ]
    Percentage of participants achieving a CR at any time during the study as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  4. Duration of Complete Response Rate [ Time Frame: Approximately 24 months ]
    Time from the first documentation of CR to the first documentation of PD as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  5. Progressive-free survival [ Time Frame: Approximately 24 months ]
    Time from enrollment until PD or death as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  6. 12-month Progressive-free survival [ Time Frame: Approximately 30 months (18 months for enrollment plus 12 months follow-up for the last participant enrolled) ]
    Percentage of participants without PD or death at 12 months after their first dose of study intervention as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  7. Event free survival [ Time Frame: Approximately 24 months ]
    Time from enrollment to PD, death, or start of new treatment as assessed by an IRC per the Lugano criteria with LYRIC modification or RECIST 1.1

  8. Area Under the Curve (AUC) of the blood levels of STI-3031 [ Time Frame: Approximately 24 months ]
    Measure the actual body exposure to STI-3031

  9. Maximum Plasma Concentration (Cmax) of STI-3031 [ Time Frame: Approximately 24 months ]
    Measure the maximum (or peak) blood concentration of STI-3031

  10. Time of Maximum concentration observed (Tmax) of STI-3031 [ Time Frame: Approximately 24 months ]
    Measure the is the time at which the maximum blood concentration of STI-3031 is observed

  11. Half-life (t1/2) of STI-3031 [ Time Frame: Approximately 24 months ]
    Measure the time it takes for the concentration of the drug in the blood to be reduced by 50%

  12. Immunogenicity [ Time Frame: Approximately 24 months ]
    Incidence of anti-drug antibody (ADA) (serum titers of anti-STI-3031 antibodies) and correlation with exposure and activity

  13. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031 [ Time Frame: Approximately 24 months ]
    Terms, frequency, severity and seriousness of adverse events (AEs) and relationship of AEs to STI-3031 the actual body exposure to drug after administration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene abnormality or Epstein-Barr virus positivity, or biliary tract cancer.
  • Prior treatment:

    • Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of systemic therapy including an asparaginase-based regimen.
    • Peripheral T-cell lymphoma: must have received at least 1 previous line of systemic multi-agent chemotherapy. Participants with anaplastic large cell lymphoma (ALCL) must have received brentuximab vedotin
    • Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of systemic therapy including an anti-CD20 antibody
    • Biliary Tract Cancer: Must have received at least 1 previous line of systemic therapy including gemcitabine with or without platinum
  • Documented disease progression during or after the last therapy
  • If not previously treated with transplant, Investigator considers the participant ineligible for transplant
  • Measurable disease
  • Adult age (as defined by respective country) at time of signing informed consent form (ICF)
  • Must be able to understand the nature of the study and provide a signed and dated, written ICF prior to any study-specific procedures, sample collections and analyses
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
  • Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed since the end of treatment
  • At least 14 days or 5 half-lives must have elapsed since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2
  • Adequate hematologic, renal and hepatic function
  • Females of childbearing potential (FCBP) must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study intervention
  • Male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study intervention
  • Predicted life expectancy of at least 16 weeks

Exclusion Criteria:

  • Current participation in another therapeutic clinical trial
  • Prior treatment with an anti-PD-L1 or anti-PD-1 antibody
  • Patients with symptomatic central nervous system (CNS) metastases unless considered adequately treated and controlled for at least 2 weeks
  • Prior hematopoietic stem cell transplantation
  • History of other previous cancer that would interfere with the determination of safety or efficacy
  • Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus
  • Apparent active or latent tuberculosis (TB) infection
  • Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
  • Seropositive for or have active viral infection with hepatitis B virus (HBV), unless HBV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
  • Seropositive for or active viral infection with HIV, unless the following are met:

    • CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and
    • Participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to screening and have HIV viral load < 400 copies/mL; and
    • Participant has not had acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months prior to screening
  • Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days
  • Evidence of bleeding diathesis or coagulopathy.
  • Significant proteinuria
  • Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
  • Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention
  • Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor
  • History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
  • Known current drug or alcohol abuse
  • Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤7 days prior to the first dose of study intervention
  • Pregnant or lactating
  • Any of the following cardiac diseases currently or within the last 6 months:

    • QT interval corrected using Fridericia's formula >450 milliseconds in men and > 470 milliseconds in women (up to 480 milliseconds may be allowed after discussion between the Investigator and the Medical Monitor).
    • Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Unstable angina pectoris
    • Congestive heart failure (New York Heart Association ≥ Grade 2)
    • Acute myocardial infarction
    • Clinically significant conduction abnormality not controlled with pacemaker or medication
    • Significant ventricular or supraventricular arrhythmias (Participants with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible.)
  • Underlying medical conditions that, in the opinion of the investigator and/or medical monitor, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03999658


Contacts
Layout table for location contacts
Contact: Ken Takeshita, MD +1-908-656-1283 ktakeshita@sorrentotherapeutics.com

Sponsors and Collaborators
Sorrento Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Ken Takeshita, MD Sorrento Therapeutics

Layout table for additonal information
Responsible Party: Sorrento Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03999658     History of Changes
Other Study ID Numbers: STI-3031-001
First Posted: June 27, 2019    Key Record Dates
Last Update Posted: June 27, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sorrento Therapeutics, Inc.:
cholangiocarcinoma
gall bladder cancer
ENKTL
DLBCL
PTCL
relapsed
refractory
T/NK-cell
NK/T-cell
peripheral T-cell
PD-L1
anti-PD-L1 antibody

Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Lymphoma
Lymphoma, B-Cell
Lymphoma, T-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell, Peripheral
Lymphoma, Extranodal NK-T-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Biliary Tract Diseases
Digestive System Diseases
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs